Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

NCT ID: NCT02107235

Last Updated: 2017-06-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2015-01-31

Brief Summary

The working hypothesis is that oral rigosertib treatment when added to platinum-based Chemoradiotherapy (CRT) will improve progression-free survival for first-line patients with intermediate- or high-risk human papillomavirus negative positive (HPV (+)) Head and Neck Squamous Cell Carcinoma. This study will determine the highest safe dose of oral rigosertib that can be used with cisplatin and CRT. This study will also record any side effects that may occur and measure tumor sizes and how long patients live.

Detailed Description

This is a multicenter, dose-escalating study of oral rigosertib administered with concurrent cisplatin and Radiotherapy in patients with intermediate- and high-risk Head and Neck Squamous Cell Carcinoma.

Three rigosertib escalating cohorts (up to 6 patients per cohort) will be sequentially evaluated: 70 mg 3 times a day (TID), 140 mg TID and 280 mg TID. The total treatment course will be 8 weeks: 1 week of oral rigosertib alone (70 mg TID, 140 mg TID or 280 mg TID) followed by 7 weeks of concurrent administration of rigosertib, cisplatin and radiation therapy.

After completion of treatment, patients will be followed for up to 36 months to document Progression-free Survival and Overall Survival.

Conditions

Head and Neck Neoplasms; Carcinoma, Squamous Cell

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Rigosertib + Cisplatin + Radiation

Oral rigosertib will be started 7 days before initiation of concurrent treatment with cisplatin and radiation therapy and will be administered on a continuous basis for a fixed duration of 8 weeks. Three oral rigosertib escalating doses will be sequentially evaluated: 70 mg 3 times a day (TID), 140 mg TID and 280 mg TID.

Cisplatin will be administered intravenously at a dose of 40 mg/m^2 on Days 1, 8, 15, 22, 29, 36, and 43 of the 7-week concurrent treatment course.

The prescribed radiotherapy dose will be 70 Gray (Gy) in 2 Gy once-daily fraction size (total of 35 fractions) over the 7-week concurrent treatment course. The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, 5 fractions per week.

Group Type: EXPERIMENTAL

oral rigosertib

Intervention Type: DRUG

cisplatin

Intervention Type: DRUG

Radiotherapy

Intervention Type: RADIATION

Interventions

oral rigosertib

Intervention Type: DRUG

cisplatin

Intervention Type: DRUG

Radiotherapy

Intervention Type: RADIATION

Other Intervention Names

ON 01910.Na; rigosertib sodium

Eligibility Criteria

Inclusion Criteria

1. Pathologically confirmed diagnosis of Squamous Cell Carcinoma of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal wall), hypopharynx, or larynx.

2. Patient is an appropriate candidate for definitive chemoradiotherapy.

3. Intermediate-risk Head and Neck Squamous Cell Carcinoma (HNSCC), defined as follows:

1. Clinical stage T2-4, N2a-N3 or T3-4, N0-N3

2. P16 (+) by immunohistochemistry (IHC) or HPV (+) by in situ hybridization (ISH)

3. Smoking status of ≥ 10 pack-years, or < 10 pack-years and T4 or N2c-N3.

4. If not intermediate-risk HNSCC, is high-risk HNSCC, defined as follows:

1. Clinical stage T2-4, N2a-N3 or T3-4, N0-N3.

2. P16 (-) by IHC or HPV (-) by ISH.

5. No evidence of distant metastases.

6. Clinically or radiographically evident measurable disease (as defined by RECIST v 1.1) at the primary site or nodal stations.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

8. Adequate hematologic function as defined by absolute neutrophil count (ANC) ≥ 1800/μL; platelet (PLT) ≥ 100,000/μL; Hgb ≥ 8.0 g/dL.

9. Adequate renal function, as defined by serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min.

10. Adequate liver function as defined by total bilirubin ≤ 1.5 x ULN; aspartate transaminase (AST)/alanine transaminase (ALT) ≤ 2.5 x ULN; and prothrombin time ≤ 1.5 x ULN, unless receiving therapeutic anticoagulation.

11. Ability to understand the nature of the study and any hazards of study participation, to communicate satisfactorily with the Investigator, and to follow the requirements of the entire protocol.

12. Willingness to adhere to the prohibitions and restrictions specified in this protocol.

13. The patient must sign an informed consent form (ICF) indicating that s/he understands the purpose of and procedures required for the study and is willing to participate in the study.

Exclusion Criteria

1. Gross total excision of the primary and nodal disease.

2. Prior treatment with IV or oral rigosertib.

3. Prior chemotherapy for the study HNSCC cancer.

4. Prior radiotherapy to the region of the study HNSCC cancer or adjacent anatomical sites, or to > 25% of marrow-bearing area.

5. Synchronous malignancies.

6. Prior invasive malignancy unless the patient is disease-free for a minimum of 3 years; however, patients with prior non-melanoma skin cancer, cervical intraepithelial neoplasia (CIN), or prostate cancer with undetectable prostate-specific antigen (PSA) may be enrolled.

7. Severe, active comorbidity.

8. Known infection with human immunodeficiency virus (HIV).

9. Any uncontrolled condition that, in the opinion of the Investigator, could affect the subject's participation in the study.

10. Major surgery within 3 weeks of enrollment or major surgery without full recovery.

11. Ascites requiring active medical management, including paracentesis.

12. Hyponatremia (defined as serum sodium < 130 milliequivalent mEq/L) or conditions that may predispose patients to hyponatremia.

13. Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 110 mmHg, despite treatment with 2 antihypertensive agents.

14. New onset of seizures within 3 months prior to enrollment, or poorly controlled seizures.

15. Female patients who are pregnant or lactating.

16. Female patients of childbearing potential and male patients with partners of childbearing potential who are unwilling to follow strict contraception requirements.

17. Female patients of childbearing potential who do not have a negative blood or urine pregnancy test at Screening.

18. History of allergic reactions attributed to compounds of similar chemical or biologic composition to rigosertib.

19. Prior therapy with a phosphatidyl-inositol 3 kinase (PI3K), Akt or mammalian target of rapamycin (mTOR) inhibitor.

20. Any other investigational agent or chemotherapy, radiotherapy, or immunotherapy within 4 weeks of enrollment.

21. Psychiatric illness/social situations that would limit the patient's ability to tolerate and/or comply with study requirements, or inability to comply with study and/or follow-up procedures.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Traws Pharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Antonio Jimeno, MD, PhD

Role: STUDY_CHAIR

University of Colorado, Denver

Locations

University of Colorado Cancer Center

Aurora, Colorado, United States

Christiana Care Health Services

Newark, Delaware, United States

Montefiore Medical Center

The Bronx, New York, United States

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Countries

United States

References

Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.

Reference Type: RESULT

Other Identifiers

Onconova 09-12

Identifier Type: -

Identifier Source: org_study_id